Google diabetic lenses won't arrive this year

[ad_1]

Contact lenses from the Google Verily subsidiary will not arrive at the end of 2016. These lenses must allow the detection of the glucose level in diabetics. It was Alcon, a subsidiary of the pharmaceutical giant Novartis and a partner of Google and Verily in the development of these lenses, who announced that they could not meet the deadlines they had set for themselves.

Of all the craziest projects carried by Google – the famous moonshots– that of Verily, formerly Google Life Sciences, is perhaps one of the most remarkable. This involves developing a lens that can detect the glucose level in diabetics. A slightly crazy project that is late, despite the partnership that Google had concluded now two years ago with Alcon, a subsidiary of the pharmaceutical and medical giant, the Swiss Novartis.

Lenses for detecting glucose and autofocal lenses

Verily is actually working on two lens projects in collaboration with Alcon. The first one, a little less impressive at first sight, still represents quite a technical challenge. Indeed, it is a question of providing a lens which makes it possible to adapt to the view of its user to correct for example a presbyopia. Verily and Alcon have apparently missed their objective of conducting a clinical study by the end of 2016. This could therefore complicate the objective of Verily and Alcon who wished in 2014 to put these lenses on the market within five years. The second therefore concerns the lens project for detecting the glucose level for diabetics is even less advanced.

Too ambitious a goal?

Indeed, with regard to the lenses allowing the detection of glucose, it could take much longer. According to some, including the specialized publication Stat, this is even almost impossible. Indeed, measuring the glucose level in diabetics requires a blood Review, and a lacrimal analysis would not be enough to obtain sufficiently reliable results. However, a poor detection of the glucose level can mean an incorrect insulin dosage, which can endanger the life of a diabetic person. One wonders if the Google subsidiary will one day begin trials on this project, since unlike the first type of lens mentioned, it has no date or objective for a clinical Review …

[ad_2]

AB SMART HEALTH health home & BUILDING REVIEW